Alaunos Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

TCRT$1.67-4.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ALAUNOS THERAPEUTICS, INC.
Date: March 31, 2025	By:	/s/ Dale Curtis Hogue, Jr.
		Dale Curtis Hogue, Jr.
		Interim Chief Executive Officer and Director
		(Principal Executive Officer and Principal Financial Officer)
Date: March 31, 2025	By:	/s/ Ferdinand Groenewald
		Ferdinand Groenewald
		Vice President, Finance
		(Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Dale Curtis Hogue, Jr.
Signature	Title	Date
Dale Curtis Hogue, Jr.	Interim Chief Executive Officer and Director (Principal Executive Officer and Principal Financial Officer)	March 31, 2025
/s/ Ferdinand Groenewald
Ferdinand Groenewald	Vice President, Finance (Principal Accounting Officer)	March 31, 2025
/s/ Robert Hofmeister
Robert Hofmeister	Director	March 31, 2025
/s/ Robert W. Postma
Robert W. Postma	Director	March 31, 2025
/s/ Jaime Vieser
Jaime Vieser	Director	March 31, 2025
/s/ Holger Weis
Holger Weis	Director	March 31, 2025

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.